24/7 Market News Snapshot 18 August, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)

August 18, 2025

DENVER, Colo., 18 August, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc. is experiencing a notable surge in its stock price, rising to $4.281, marking an impressive increase of 53.99% from the previous day’s close of $2.780. The pre-market trading saw an astonishing volume of 8.85 million shares exchanged, indicating a strong bullish sentiment among investors. This surge reflects mounting confidence in Soligenix’s innovative biopharmaceutical initiatives, particularly its groundbreaking therapy SGX945, which recently received orphan drug designation from the United States Food and Drug Administration (FDA) for the treatment of Behçet’s Disease.

Behçet’s Disease is a serious inflammatory disorder affecting approximately 18,000 individuals in the U.S., highlighting a significant unmet medical need. The FDA’s orphan drug designation not only grants Soligenix seven years of market exclusivity upon final approval but also provides access to various regulatory and financial incentives that are crucial for the drug’s development. The recent Phase 2a clinical trial of dusquetide, the active ingredient in SGX945, yielded encouraging results, demonstrating both efficacy and safety for patients afflicted by this challenging condition.

Dr. Christopher J. Schaber, President and CEO of Soligenix, expressed enthusiasm for the potential of dusquetide, emphasizing the significance of this treatment for individuals with limited options. Dusquetide acts as an innate defense regulator, aiming to modulate the body’s inflammatory response without direct antibiotic properties. Its prior success in managing oral mucositis from cancer therapies further reinforces its promise.

As Soligenix continues advancing SGX945 through the regulatory landscape, the company remains committed to its mission of delivering transformative therapies for rare diseases, striving to enhance the quality of life for patients globally. The convergence of increasing investor interest and significant therapeutic advancements positions Soligenix as a noteworthy player in the biopharmaceutical sector.

Related news for (SNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.